{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small-Cell+Lung+Cancer+%28SCLC%29&page=37",
    "query": {
      "condition": "Small-Cell Lung Cancer (SCLC)",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 3990,
    "total_pages": 399,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small-Cell+Lung+Cancer+%28SCLC%29&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small-Cell+Lung+Cancer+%28SCLC%29&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T14:29:37.118Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05672108",
      "title": "Phase II Trial of Lung Chemoemobolization",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Non-Small Cell Carcinoma",
        "Mediastinal Neoplasm",
        "Pleural Neoplasm",
        "Lung Metastases From Any Primary",
        "Endobronchial Metastases",
        "Colon Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ethiodized Oil",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Transarterial Chemoembolization",
          "type": "PROCEDURE"
        },
        {
          "name": "Tris-acryl Gelatin Microspheres",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-05-12",
      "completion_date": "2027-10-28",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 2,
      "location_summary": "Duarte, California • New York, New York",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05672108"
    },
    {
      "nct_id": "NCT03997968",
      "title": "A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignancy",
        "Non-hodgkin Lymphoma",
        "Multiple Myeloma",
        "Breast Cancer",
        "Ovarian Cancer",
        "Soft Tissue Sarcoma",
        "Head and Neck Cancer",
        "DLBCL",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Pancreatic Cancer",
        "CLL",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "CYT-0851",
          "type": "DRUG"
        },
        {
          "name": "CYT-0851 in combination with gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "CYT-0851 in combination with capecitabine",
          "type": "DRUG"
        },
        {
          "name": "CYT-0851 in combination with rituximab and bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cyteir Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2019-10-09",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Stanford, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997968"
    },
    {
      "nct_id": "NCT01229150",
      "title": "Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "AZD6244",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "AZD6244 + Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2010-10-26",
      "completion_date": "2015-11-21",
      "has_results": true,
      "last_update_posted_date": "2017-05-23",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 5,
      "location_summary": "Davis, California • Los Angeles, California • South Pasadena, California + 2 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01229150"
    },
    {
      "nct_id": "NCT00095225",
      "title": "A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma",
        "Neoplasm Recurrence, Local"
      ],
      "interventions": [
        {
          "name": "Avastin (bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "Tarceva (erlotinib HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2004-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2008-01-29",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 48,
      "location_summary": "Bakersfield, California • Concord, California • Fullerton, California + 40 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Laverne",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095225"
    },
    {
      "nct_id": "NCT00101413",
      "title": "BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Carcinoma, Non-Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar, BAY43-9006)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2004-04",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101413"
    },
    {
      "nct_id": "NCT06567015",
      "title": "Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "STX-241",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2024-09-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06567015"
    },
    {
      "nct_id": "NCT03910660",
      "title": "A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Neuroendocrine Tumors",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "BXCL701 plus Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "BXCL701 monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioXcel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 98,
      "start_date": "2019-02-12",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03910660"
    },
    {
      "nct_id": "NCT07038343",
      "title": "AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor Cancer",
        "Locally Advanced",
        "Metastatic Solid Tumors",
        "Lung Cancers",
        "Epithelial Tumor",
        "Biliary Tract Cancer (BTC)",
        "Urothelial Cancer",
        "Nasopharyngeal Cancers"
      ],
      "interventions": [
        {
          "name": "AVZO-1418",
          "type": "DRUG"
        },
        {
          "name": "Combination Agent 1",
          "type": "DRUG"
        },
        {
          "name": "Combination Agent 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avenzo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 480,
      "start_date": "2025-06-04",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 19,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07038343"
    },
    {
      "nct_id": "NCT01857271",
      "title": "Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2013-11",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2020-07-08",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 3,
      "location_summary": "New York, New York • The Bronx, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01857271"
    },
    {
      "nct_id": "NCT06555263",
      "title": "Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Lung Cancer Metastatic",
        "Lung Cancer, Nonsmall Cell",
        "Lung Cancer Non-Small Cell Stage IIIB",
        "Lung Cancer Non-small Cell Stage IV",
        "Lung Cancer, Non-small Cell"
      ],
      "interventions": [
        {
          "name": "Luveltamab tazevibulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-21",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-10-16T14:29:37.118Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Lake Mary, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06555263"
    }
  ]
}